Reportlinker Adds The Future of Nutrigenomics: New Opportunities in Personalized Nutrition and Food-Pharma Collaboration
NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Nutrigenomics explores how nutrients or bioactive dietary compounds can influence gene expression and an individuals risk to certain diseases. Nutrigenetics is the study of how variations in an individual's genetic makeup can increase or decrease the need for a specific nutrient or bioactive food component.
Nutrigenomics has the potential to impact various parts of the food chain including the genetic modification of crops and animal feeds, the development of nutrigenomic tests to monitor food safety and personalization of diets, as well as the identification of nutritional supplements and nutrigenomic based products which may offer potential health benefits.
The consumer environment is driving growth in the Nutrition & Health market. Over the past decade, consumers have become more concerned for their health and are increasingly inclined to invest in DTC nutrigenetic tests to assess their risk of disease and obtain dietary advice. Healthcare providers too, are keen to shift some of the burden of healthcare costs to individuals and recognize that the personalization of nutrition may be beneficial. The Health and nutrition market is currently worth around $485 billion.
This report reviews the business strategies of leading companies regarding the adoption of nutrigenomic technologies and establishment of public-private partnerships as well as potential opportunities for biomarker discovery with the pharma and diagnostic industry to personalize nutrition and medicine.
Key features of this report
- Identify leading academic groups and companies at the forefront of the nutrigenomic research who will drive the market towards a more personalized approach to nutrition and disease prevention.
- Assess the nutrigenomic testing market, leading companies and its role in empowering consumers to take a more active role in making dietary decisions and maintaining their health status
- Review the backgrounds, strategies and business models of companies and assess potential opportunities to collaborate with the pharma and diagnostic industry.
Scope of this report
- Identify the companies leading the field in nutrigenomic research from ingredient & food manufacturers to nutrigenomic testing companies
- Review their key products and business alliances which enable them to participate in this evolving field of science
- Identify points of convergence of the pharma, diagnostic and food and drinks markets which may offer new opportunities for co development
- Review market drivers regarding the adoption of nutrigenomic information and the personalization of nutrition.
Key Market Issues
- The food market is changing: Over the past decade, consumers have become more concerned for their health and wellbeing. The roll of the food and drinks industry is changing and shifting towards a more benefit driven and preventative approach. In order to respond to market dynamics the companies have needed to adopt an "open network" model to gain access to innovative research and technologies which will drive future product development.
- Nutrigenomics & pharmacogenomics are related in their approach to identify subpopulations that respond to treatment/nutrition. The application of these technologies may lead to the identification of old and new ingredients that have beneficial effects for specific consumer groups, helping to maintain health and wellness and leading to the personalization of treatment and diets. The scientific evidence is mounting however, large scale clinical studies are needed to reinforce data which can be utilized initially in dietary guidance and latterly to support health claims.
- Nutrigenomic testing marketing is growing and has been fueled by consumer concerns for their health and the demand for genomic information. Increasingly, consumers are inclined to invest in DTC nutrigenomic tests to assess their health status and obtain dietary guidance. This market is currently estimated to be worth US$730 million and growing by 20% per annum.
Key findings from this report
- The food and drinks industry has been undergoing major regulatory changes during the last few years, particularly with respect to health and dietary claims. Added to this, the adoption and application of nutrigenomic technologies, may provide additional clinical data to substantiate claims and provide new opportunities to develop products which target consumer sub groups. This may require further adjustments in the regulatory framework to stimulate innovation but ensure consumer safety.
- There are significant market opportunities for the development of nutrigenomic tests and products which target consumer groups. Successful products will need to be supported by robust and reproducible clinical studies - these will cost time and money and will only be feasible through public / private collaborations. The results will enable the manufacturer to clearly differentiate themselves and target specific groups – leading to fragmentation of the market and a shift in he healthcare paradigm from treatment towards prevention.
- Synergies exist between the food and drinks industry and the pharma and diagnostic industry that may create opportunities (e.g. biomarker discover) but also lead to conflicts as the food manufacturers aim to keep consumers healthier for longer forcing pharma to switch to a more preventative strategy by targeting lifestyle disease (e.g. obesity) as their pool of unhealthy ill patients contracts.
Key questions answered
- Which companies are involved in nutrigenomic testing and how may they influence the uptake of personalised nutrition?
- How are Health and Nutrition market leaders applying nutrigenomic research in their R&D programs to develop new products or create new marketing opportunities?
- What potential opportunities exist between the food and drinks industry and the pharma and diagnostic industry to co-develop biomarkers for the development of personalised nutrition and medicine.
Companies mentioned
BASF, Chr. Hansen, DSM, Danone, Nestle, Unilever, GeneLink, Gene Smart, Genova Diagnostics, Interleukin Genetics Inc,
Table of Contents
The Future of Nutrigenomics
Executive summary 10
Defining nutrigenomics 10
Market drivers 11
Collaborative nutrigenomic research & consortia 12
Leading food & drinks companies: nutrigenomic strategies 13
Leading nutrigenomic testing companies 14
Opportunities: convergence of pharma & diagnostics 15
Challenges: regulation, ethical & IP issues 16
Conclusions 17
Chapter 1 Defining nutrigenomics 20
Summary 20
Introduction 21
'Omic technologies 23
Nutrigenomics and the food & drinks industry 26
Nutrigenomics & food products 28
Nutrigenomics & personalized nutrition 28
Report outline 29
Chapter 2 Market drivers 32
Summary 32
Introduction 33
Drivers for personalized nutrition 34
Healthy aging 34
Consumer demographics 36
Chronic non-communicable disease 38
Urbanization and the emerging markets 40
Global health economics 41
Conclusions on drivers for personalized nutrition 42
Chapter 3 Collaborative nutrigenomic research & consortia 46
Summary 46
Introduction 47
Nutrigenomic research consortia 47
Nutrigenomic research in the EU 49
The European Nutrigenomics Organization (NuGO) 49
DiOGenes 51
TI Food and Nutrition 51
Vision EpiFood Project 53
Canada Foundation for Innovation (CFI) 53
Public-private in age-related diseases 53
Nutrigenomic research in the US 55
Public-private partnership: genetically modified crops 57
Nutrigenomic research across the world 58
International Society of Nutrigenetics/Nutrigenomics (ISNN) 58
Conclusions 59
Chapter 4 Leading food & drinks companies: nutrigenomic strategies 62
Summary 62
Introduction 63
Ingredients manufacturers approach to nutrigenomics 64
BASF 64
Chr Hansen 66
DSM 69
Food manufacturers' approach to nutrigenomics 73
Group Danone 73
Nestle 76
Unilever 78
Pharma industry M&A in consumer nutrition 80
The evolving open network model 82
Co-development opportunities 86
Areas for market growth & time scales 88
Conclusions 90
Chapter 5 Leading nutrigenomic testing companies 94
Summary 94
Introduction 95
Market leaders 95
23andme.com 97
GeneLink 98
Gene Smart 98
Genova Diagnostics 99
Interleukin Genetics Inc 100
WellGen Inc. 102
Conclusions 104
Chapter 6 Opportunities: convergence of pharma & diagnostics 108
Summary 108
Introduction 109
Nutrigenomics vs pharmacogenomics 110
Global health issues treatment vs prevention 115
Convergence of the pharmaceutical & diagnostic market 116
Conclusions 118
Chapter 7 Challenges: regulation, ethical & IP issues 120
Summary 120
Introduction 121
Regulation of nutrigenomic foods 122
Europe 123
Japan 124
Regulation of nutrigenomic tests 125
Ethical issues 127
Public awareness & perceptions 128
Intellectual Property 129
Conclusions 131
Chapter 8 Conclusions 134
Summary 134
The food & drinks market 135
Global genetic testing market 136
Market trends 136
Overall conclusions 137
Appendix 140
Primary research methodology 140
Acknowledgments 141
Glossary 142
Index 145
Bibliography 148
Endnotes 151
List of Figures
Figure 1.1: Nutrigenetics and nutrigenomics 22
Figure 1.2: The 'omics technologies 24
Figure 1.3: The functional genomic tool box 26
Figure 1.4: Applications of nutrigenomics in the food chain 27
Figure 2.5: Drivers for the food & drinks industry 33
Figure 2.6: The ageing population a driver for personalized nutrition 35
Figure 2.7: Personalized nutrition targeting consumer segments 36
Figure 2.8: Population over 60: world and developed regions (1950-2050) 37
Figure 2.9: Nutritional challenges – obesity & metabolic syndrome 38
Figure 2.10: Growth in consumers in developing & emerging countries (2008-2018) 40
Figure 2.11: Healthcare expenditure as a share of GDP (2006) 41
Figure 2.12: Target population of nutrigenomic based products 43
Figure 4.13: BASF approach to gene discovery 65
Figure 4.14: DSMs sales growth targeting four emerging business areas 70
Figure 4.15: DSMs R&D competencies 72
Figure 4.16: An International and interdisciplinary network 75
Figure 4.17: Diversify & de-risk through externalization 84
Figure 4.18: Open network model 85
Figure 4.19: Waves of nutrigenomic development 90
Figure 5.20: WellGen's nutrigenomic based discovery 103
Figure 6.21: Nutrigenomics vs pharmacogenomics 111
Figure 6.22: Relationship of drugs, disease, genes and gene products 113
Figure 8.23: Health and nutrition market segments (2009) 135
Figure 8.24: Nutrigenomic impact on personalized nutrition 139
List of Tables
Table 3.1: European Consortia and Nutrigenomic Research Programs 50
Table 3.2: Nutrigenomics Network Programs 55
Table 4.3: Stakeholders in nutrigenomic research and personalized nutrition 63
Table 4.4: Chr Hansen - strategic alliances & investments 67
Table 4.5: Nestle nutrigenomic alliances & investments 77
Table 4.6: Divestment of Animal, Consumer & Medical Nutrition Divisions 80
Table 4.7: Consumer Health Divisions of Pharmaceutical Companies 81
Table 4.8: Alliance between Food, Pharma, Biotech and the Diagnostic Industries 82
Table 5.9: Categorization of genetic variations that may be included in nutrigenomic tests 96
Table 5.10: Categorization of genetic variations that may be included in nutrigenomic tests 97
Table 6.11: Known diet- gene interactions 112
Table 6.12: Known gene-nutrient interactions 114
To order this report:
Nutraceutical Industry: The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Newsrooms &
Influencers

Digital Media
Outlets

Journalists
Opted In
Share this article